Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema

A Placebo-controlled Randomized Trial to Evaluate the Efficacy and Safety of GNR-038 in Comparison With Berinert® for Acute Attacks Relief in Patients With Hereditary Angioedema

It is a placebo-controlled randomized trial to evaluate the efficacy and safety of GNR-038 in comparison with Berinert® in patients with hereditary angioedema

Study Overview

• Status: Withdrawn
• Conditions: Hereditary Angioedema
• Intervention / Treatment: Drug: GNR-038, 50 МЕ/ kg; Drug: GNR-038, 100 МЕ/ kg; Drug: Berinert®, 20 МЕ/ kg; Drug: Placebo; Drug: GNR-038. The dose will be selected according to results of stage 1 clinical trial.

Detailed Description

Hereditary angioedema is a rare, potentially life-threatening genetically determined disease associated with a deficiency or impairment of the functional activity of the C1-esterase inhibitor (C1-inhibitor). The main clinical manifestation of hereditary angioedema is recurrent subcutaneous or submucosal swelling of various localization. Most often, the development of the disease is based on a mutation in the SERPING1 gene. The prevalence of the disease in the world ranges from 1:10 000 to 1:150 000. GNR-038 is a recombinant C1 inhibitor (rhC1INH), which is a complete structural and functional analog of the plasma C1 inhibitor. Phase I study results showed convincing safety and tolerability evidence of GNR-038.

• Study Type: Interventional
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• Russian Federation
  • Moscow, Russian Federation, 115522
    • National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia
  • Moscow, Russian Federation, 123182
    • Moscow City Clinical Hospital 52
  • Moscow, Russian Federation, 630099
    • Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology
  • Rostov-on-Don, Russian Federation, 344022
    • Rostov State Medical University
  • Stavropol', Russian Federation, 355000
    • LLC "Scientific Medical Center of General Therapy and Pharmacology"

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria

1. Men and women 18 years and older at the time of signing the Informed Consent Form.
2. Availability of written informed consent signed by the patient prior to the start of any procedures related to the study.

3. Confirmed diagnosis of HAE:

   • C4 level <50% of the lower limit of the range of normal laboratory values and one of the points below:
   • the C1INH level <50% of the lower limit of the range of normal laboratory values, OR
   • the level of C1INH within normal values, while the level of functional activity of C1INH is below 50% of the lower limit of the range of normal values.
4. Localization of the edema in the abdominal cavity, in the face area (lips, eyelids, subcutaneous tissue), limbs, trunk or in the area of the external genitals in the anamnesis.
5. ≥4 HAE attacks requiring treatment or causing significant functional impairment for 2 consecutive months in the 3-month period prior to Screening, properly documented in the medical records.
6. Patient's consent to adhere to reliable methods of contraception.

Exclusion Criteria

1. Deviation of the C1q level below the normal limit.
2. B-cell lymphoproliferative diseases in the anamnesis or at the time of inclusion in clinical trial.
3. The presence of anti-C1INH autoantibodies.
4. Allergic reactions to the components of C1INH drugs or other blood components.
5. Glomerular filtration rate ≤59 ml/min/1.73 m2, calculated by the formula CKD-EPI Creatinine Equation (2009) (see Appendix).
6. The concentration of peripheral blood leukocytes >20*109/L.
7. Drug addiction, solvent abuse, alcoholism in the anamnesis or at the time of inclusion.
8. Participation in clinical trials of C1-esterase inhibitor drugs, blood transfusion and its components during the last 90 days prior to screening.
9. Participation in clinical trials of any other investigational drugs within the last 30 (thirty) days prior to screening.
10. Positive laboratory results for HIV and hepatitis B and C.
11. Pregnancy and lactation.
12. Diseases and conditions associated with thrombosis (myocardial infarction, transient ischemic attacks, deep and superficial vein thrombosis, and pulmonary embolism) less than 6 months before the start of the screening period, as well as an increased risk of arterial or venous thrombosis according to the study doctor's opinion.

13. Concomitant diseases and conditions that according to the study doctor's opinion put the patient's safety at risk when participating in the study, or that will affect the analysis of safety data if this disease/condition worsens during the study, including:

    • Mental illness;
    • Diseases of the immune and endocrine system that are not controlled by drug therapy (including decompensated diabetes mellitus and thyroid diseases);
    • Hematological diseases requiring chemotherapy;
    • Cancer or cancer in the past medical history, with the exception of cured basal cell carcinoma;
    • Decompensated liver diseases.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Study stage 1: GNR-038, 50 МЕ/ kg; Recombinant C1 esterase inhibitor	Drug: GNR-038, 50 МЕ/ kg; A single intravenous infusion of GNR-038, 50 МЕ/ kg less than 5 hours after the onset of edema.; Other Names: Recombinant C1 esterase inhibitor, 50 МЕ/ kg
Experimental: Study stage 1: GNR-038, 100 МЕ/ kg; Recombinant C1 esterase inhibitor	Drug: GNR-038, 100 МЕ/ kg; A single intravenous infusion of GNR-038, 100 МЕ/ kg less than 5 hours after the onset of edema.; Other Names: Recombinant C1 esterase inhibitor, 100 МЕ/ kg
Experimental: Study stage 1: Berinert®, 20 МЕ/ kg; Human C1 esterase inhibitor	Drug: Berinert®, 20 МЕ/ kg; A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.; Other Names: Human C1 esterase inhibitor
Experimental: Study stage 1: Placebo; Placebo	Drug: Placebo; A single intravenous infusion of Placebo less than 5 hours after the onset of edema.
Experimental: Study stage 2: GNR-038 in selected dose; Recombinant C1 esterase inhibitor	Drug: GNR-038. The dose will be selected according to results of stage 1 clinical trial.; A single intravenous infusion of GNR-038 less than 5 hours after the onset of edema.; Other Names: Recombinant C1 esterase inhibitor.
Experimental: Study stage 2: Berinert®, 20 МЕ/ kg; Human C1 esterase inhibitor	Drug: Berinert®, 20 МЕ/ kg; A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.; Other Names: Human C1 esterase inhibitor

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to symptoms relief onset of acute HAE attack within 24 hours after the end of the drug administration.	A persistent decrease in the intensity of symptoms by 20 mm from the initial level on the visual analogue scale (VAS) will be regarded as a relief of symptoms of HAE. 0 mm is the absence of symptoms, 100 mm is the maximum possible intensity of symptoms	24 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to complete resolution of the symptoms of an acute HAE attack within 24 hours after the end of the study drug administration.	Persistent absence of symptoms - 0 (zero) mm on the visual analogue scale (VAS). 0 mm is the absence of symptoms, 100 mm is the maximum possible intensity of symptoms	24 hours
Time to minimum manifestation onset of acute HAE attack symptoms after the completion of study drug administration.	Persistent reduction in the intensity of symptoms below 20 (twenty) mm on the visual analogue scale(VAS). 0 mm is the absence of symptoms, 100 mm is the maximum possible intensity of symptoms	24 hours
The proportion of HAE exacerbation episodes that achieved symptom relief after 1 hour and 4 (four) hours after the end of study drug administration.		1 hour; 4 hours.
The rate of attacks with HAE current localization relapse or with the occurrence of a new acute attack of a different localization within 24 (twenty-four) hours after the study drug administration.		24 hours
The rate of attacks that required additional administration of emergency drugs (human C1-esterase inhibitor or icatibant).		24 hours
The rate of attacks that did not respond therapeutically to the study drug administration	the lack of relief of HAE symptoms within 4 (four) hours after administration of the drug, the occurrence of a relapse of HAE of the current localization or the occurrence of a new acute attack of another localization within 24 (twenty-four) hours after drug administration, the need to use drugs that can weaken the symptoms of HAE (see drugs that are not recommended to treatment), within 24 (twenty-four) hours after drug administration.	4 hours; 24 hours
The intensity of acute HAE attack symptoms within 24 (twenty-four) hours after study drug administration.	HAE intensity wiil be measured by visual analogue scale (VAS). 0 mm is the absence of symptoms, 100 mm is the maximum possible intensity of symptoms	24 hours
Frequency of adverse events.		14 days
Frequency of anti-drug antibody formation.		7 and 14 days
The level of anti-drug antibodies neutralizing activity.	Laboratory measurement of antidrug antibody with neutralixing activity.	7 and 14 days

Collaborators and Investigators

• Sponsor: AO GENERIUM

Publications and helpful links

Helpful Links

• Clinical trial registry, Ministry of Health of Russian Federation
• Clinical trial registry

Study record dates

Study Major Dates

• Study Start (Anticipated): December 1, 2021
• Primary Completion (Anticipated): May 31, 2023
• Study Completion (Anticipated): May 31, 2023

Study Registration Dates

• First Submitted: May 18, 2021
• First Submitted That Met QC Criteria: May 21, 2021
• First Posted (Actual): May 24, 2021

Study Record Updates

• Last Update Posted (Actual): February 4, 2022
• Last Update Submitted That Met QC Criteria: January 21, 2022
• Last Verified: January 1, 2022

More Information

Terms related to this study

• Keywords: Hypersensitivity; Immune System Diseases; Genetic Diseases, Inborn; Mutation; HAE; Physiological Effects of Drugs; Genetic disease; Immunologic Factors; Angioedema; Hereditary angioedema; Immunosuppressive Agents; Swelling; GNR-038; C1-inhibitor; SERPING1 gene; C1-INH deficiency; Complement Inactivating Agents; Angioedemas, Hereditary; Complement C1 Inhibitor Protein; Complement C1 Inactivator Proteins
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Skin Diseases; Immunologic Deficiency Syndromes; Immune System Diseases; Hypersensitivity, Immediate; Genetic Diseases, Inborn; Skin Diseases, Vascular; Hypersensitivity; Urticaria; Hereditary Complement Deficiency Diseases; Primary Immunodeficiency Diseases; Angioedema; Angioedemas, Hereditary; Physiological Effects of Drugs; Immunosuppressive Agents; Immunologic Factors; Complement Inactivating Agents; Complement C1 Inhibitor Protein; Complement C1 Inactivator Proteins; Complement C1s
• Other Study ID Numbers: CIR-HAE-II-III; #210, April 16, 2 (Other Identifier: Ministry of Health of Russian Federation)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No